The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications

被引:63
|
作者
Alaoui-Jamali, MA
Paterson, J
Al Moustafa, AE
Yen, L
机构
[1] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada
[3] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada
[4] McGill Univ, Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada
[5] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada
关键词
erbB receptors; drug resistance; cell cycle checkpoints; DNA repair; apoptosis;
D O I
10.1139/bcb-75-4-315
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The erbB family of tyrosine kinase receptors is involved in the regulation of a variety of vital functions including cell proliferation, cell differentiation, and stress response. Alteration in the expression of erbB receptors occurs in numerous tumor types and plays an important role in cancer development, cancer progression, and susceptibility to cell killing by anticancer agents. Of particular interest is the intrinsic drug resistance associated with overexpression of the erbB-2 receptor. In general, tumor cells overexpressing erbB-2 are intrinsically resistant to DNA-damaging agents such as cisplatin. While the molecular mechanisms by which erbB-2 induces drug resistance are not yet established, there is evidence that this may be a consequence of altered cell cycle checkpoint and DNA repair mechanisms and dysregulation of apoptotic pathway(s). The apoptotic signal induced by many anticancer drugs originates at a receptor on the cell membrane and is transduced through a signaling cascade to the nucleus. Drug-induced apoptosis is dependent on the balance between cell cycle checkpoints and DNA repair mechanisms. Blockade of erbB-2 signaling using erbB-2 antagonists, dominant negative mutants, or chemical inhibitors of erbB-2 tyrosine kinase activity induces cell cycle arrest: inhibits DNA repair, and (or) promotes apoptosis. Less understood are downstream signal transduction cascades by which erbB-2 affects these regulatory mechanisms. The diversity of erbB receptors results in an interconnected network of cell signaling pathways that determine tumor cell fate in response to chemotherapy stress. Further investigations on the role of erbB-coupled signaling in the regulation of stress responsive genes an critical to understand the mechanisms by which tumor cells escape cell death, and will contribute to the development of alternative therapeutic targets to overcome intrinsic drug resistance in clinical settings.
引用
收藏
页码:315 / 325
页数:11
相关论文
共 50 条
  • [1] The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
    Kim, H
    Chan, R
    Dankort, DL
    Zuo, DM
    Najoukas, M
    Park, M
    Muller, WJ
    ONCOGENE, 2005, 24 (51) : 7599 - 7607
  • [2] The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
    Harold Kim
    Richard Chan
    David L Dankort
    Dongmei Zuo
    Monica Najoukas
    Morag Park
    William J Muller
    Oncogene, 2005, 24 : 7599 - 7607
  • [3] The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development
    Chan, R
    Hardy, WR
    Laing, MA
    Hardy, SE
    Muller, WJ
    MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (04) : 1073 - 1078
  • [4] The Tyrosine Kinase Receptor HER2 (erbB-2) From Oncogenesis to Adipogenesis
    Vazquez-Martin, Alejandro
    Jose Ortega-Delgado, Francisco
    Manuel Fernandez-Real, Jose
    Menendez, Javier A.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (05) : 1147 - 1152
  • [5] Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
    Wang, SC
    Lien, HC
    Xia, WY
    Chen, IF
    Lo, HW
    Wang, ZQ
    Ali-Seyed, M
    Lee, DF
    Bartholomeusz, G
    Fu, OY
    Giri, DK
    Hung, MC
    CANCER CELL, 2004, 6 (03) : 251 - 261
  • [6] EGF RECEPTOR AND ERBB-2 TYROSINE KINASE DOMAINS CONFER CELL SPECIFICITY FOR MITOGENIC SIGNALING
    DIFIORE, PP
    SEGATTO, O
    TAYLOR, WG
    AARONSON, SA
    PIERCE, JH
    SCIENCE, 1990, 248 (4951) : 79 - 83
  • [7] DMBA promotes erbB-2 mediated carcinogenesis through activation of estrogen receptor and receptor tyrosine kinase pathways
    Ma, Zhikun
    Kosanke, Stanley
    Carrington, Morgan
    Yang, Xiaohe
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
    Martinello, Rossella
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Nuzzo, Annamaria
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
  • [9] A Comparative QSAR Analysis of Quinazoline Analogues as Tyrosine Kinase (erbB-2) Inhibitors
    Noolvi, Malleshappa N.
    Patel, Harun M.
    Bhardwaj, Varun
    MEDICINAL CHEMISTRY, 2011, 7 (03) : 200 - 212
  • [10] Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism
    Yan Ding
    Zixing Liu
    Shruti Desai
    Yuhua Zhao
    Hao Liu
    Lewis K. Pannell
    Hong Yi
    Elizabeth R. Wright
    Laurie B. Owen
    Windy Dean-Colomb
    Oystein Fodstad
    Jianrong Lu
    Susan P. LeDoux
    Glenn L. Wilson
    Ming Tan
    Nature Communications, 3